Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Giuseppina Leonetti"'
Autor:
Carla Colombo, Gianfranco Alicandro, Valeria Daccó, Vanessa Gagliano, Letizia Corinna Morlacchi, Rosaria Casciaro, Giovanna Pisi, Michela Francalanci, Raffaele Badolato, Elisabetta Bignamini, Barbara Messore, Maria Cristina Lucanto, Giuseppina Leonetti, Massimo Maschio, Marco Cipolli, Italian Cystic Fibrosis Society (SIFC) Study Group for COVID
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251527 (2021)
ObjectiveTo describe the symptoms and clinical course of SARS-CoV-2 infection in patients with cystic fibrosis (CF).MethodsWe carried out a prospective multicentre cohort study based on 32 CF centres and 6597 patients. Centres were contacted to colle
Externí odkaz:
https://doaj.org/article/c94e88c0bf64413b90ae62941952d32a
Autor:
Maria Favia, Crescenzio Gallo, Lorenzo Guerra, Domenica De Venuto, Anna Diana, Angela Maria Polizzi, Pasqualina Montemurro, Maria Addolorata Mariggiò, Giuseppina Leonetti, Antonio Manca, Valeria Casavola, Massimo Conese
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 7, p 2398 (2020)
The treatment of cystic fibrosis (CF) patients homozygous for the F508del mutation with Orkambi®, a combination of a corrector (lumacaftor) and a potentiator (ivacaftor) of the mutated CFTR protein, resulted in some amelioration of the respiratory f
Externí odkaz:
https://doaj.org/article/2af28fec6b1140a1aa13818cfa80e423
Autor:
Donatello Salvatore, Giuseppe Cimino, Patrizia Troiani, Elisabetta Bignamini, Irene Esposito, Giuseppina Leonetti, Maurizio Zanda, Daniela Manunza, Angela Pepe
Publikováno v:
Pediatric pulmonologyREFERENCES. 57(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::301b1228ffa0655c13783fc6098520ad
https://pubmed.ncbi.nlm.nih.gov/35577767
https://pubmed.ncbi.nlm.nih.gov/35577767
Autor:
Carla, Colombo, Marco, Cipolli, Valeria, Daccò, Paola, Medino, 1 Federico Alghisi, 4 Maura Ambroni, 5 Raffaele Badolato, 6 Fiorella Battistini, 5 Elisabetta Bignamini, 7 Rosaria Casciaro, 8 Fabiana Ciciriello, 4 Mirella Collura, 9 Isabella Comello, 10 Michela Francalanci, 11 Francesca Ficili, 9 Anna Folino, Leonardi, Salvatore, 12 Giuseppina Leonetti, 13 Maria Cristina Lucanto, 14 Francesca Lucca, 3 Massimo Maschio, 15 Valeria Mencarini, 16 Barbara Messore, 17 Giovanna Pisi, 18 Giovanna Pizzamiglio, 19 Piercarlo Poli, 6 Valeria Raia, 20 Luca Riberi, 17 Mirco Ros, 10 Novella Rotolo, 12 Angela Sepe, 20 Giovanni Taccetti, 11 Pamela Vitullo, 21 and Gianfranco Alicandro1, 2
Publikováno v:
Infection
Purpose To describe the clinical course of COVID-19 in patients with cystic fibrosis (CF) and to identify risk factors for severe COVID-19. Methods We conducted a prospective study within the Italian CF Society. CF centers collected baseline and foll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cd655d485086e222e1e4114a573774
http://hdl.handle.net/11379/555352
http://hdl.handle.net/11379/555352
Autor:
Domenica De Venuto, Donatello Salvatore, Giovanna Pisi, Carlotta Biglia, Fabio Majo, Michela Francalanci, Federico Cresta, Giovanna Pizzamiglio, Maria Adelaide Calderazzo, Barbara Messore, Vito Terlizzi, Giuseppina Leonetti, Giovanni Taccetti, Mimma Caloiero
Publikováno v:
Respiratory medicine. 171
Background Ivacaftor is an innovative treatment for CF. Ivacaftor monotherapy in a phase III trial for patients with F508del and a residual function (RF) mutation showed improvement in lung function. We evaluated the effectiveness and safety of ivaca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b120044aa25a689ff67fbd12d470c6
https://pubmed.ncbi.nlm.nih.gov/32846335
https://pubmed.ncbi.nlm.nih.gov/32846335
Autor:
Lorenzo Guerra, Anna Diana, Giuseppina Leonetti, Angela Polizzi, Massimo Conese, Maria Addolorata Mariggiò, Valeria Casavola, Maria Favia, Antonio Manca, Domenica De Venuto, Pasqualina Montemurro, Crescenzio Gallo
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 2398, p 2398 (2020)
International Journal of Molecular Sciences
Volume 21
Issue 7
International Journal of Molecular Sciences
Volume 21
Issue 7
The treatment of cystic fibrosis (CF) patients homozygous for the F508del mutation with Orkambi®
a combination of a corrector (lumacaftor) and a potentiator (ivacaftor) of the mutated CFTR protein, resulted in some amelioration of the respira
a combination of a corrector (lumacaftor) and a potentiator (ivacaftor) of the mutated CFTR protein, resulted in some amelioration of the respira
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d1b2b50320e5c665f872001b4ef792b
https://www.mdpi.com/1422-0067/21/7/2398
https://www.mdpi.com/1422-0067/21/7/2398
Autor:
Anna Diana, Stefano Castellani, Sante Di Gioia, Maria Favia, Angela Polizzi, Crescenzio Gallo, Massimo Conese, Susanna D’Oria, Maria Addolorata Mariggiò, A. Vinella, Domenica De Venuto, Giuseppina Leonetti, Lorenzo Guerra, Pasqualina Montemurro
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
The role of colony stimulating factors (CSFs) in cystic fibrosis (CF) circulating neutrophils has not been thoroughly evaluated, considering that the neutrophil burden of lung inflammation in these subjects is very high. The aim of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed90c7b075952b165bae8006bb011210
https://pubmed.ncbi.nlm.nih.gov/31506515
https://pubmed.ncbi.nlm.nih.gov/31506515
Autor:
Donatello Salvatore, Michela Francalanci, Pamela Vitullo, Nicola Ferrara, Paola Iacotucci, Giuseppe Cimino, Carlo Castellani, Cesare Braggion, Vincenzina Lucidi, Carmela Colangelo, Vincenzo Carnovale, Giuseppina Leonetti, Antonio Manca
BACKGROUND Ivacaftor is a significant innovation in the treatment of cystic fibrosis (CF) with gating mutations. A substantial percentage of patients with CF have severe lung involvement, but these patients are usually excluded from phase III clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaa9601d0fd1130e6ca127a49291b2e4
http://hdl.handle.net/11588/828940
http://hdl.handle.net/11588/828940
Autor:
Luigi Ratclif, Crescenzio Gallo, Teresa Santostasi, Maria Giuseppina Pantaleo, Anna Diana, Antonio Manca, Angela Polizzi, Giuseppina Leonetti, Massimo Conese, Danila Rosa Iusco
Publikováno v:
Journal of Human Genetics. 61:473-481
Few mutations in cis have been annotated for F508del homozygous patients. Southern Italy patients who at a first analysis appeared homozygous for the F508del mutation (n=63) or compound heterozygous for the F508del and another mutation in the cystic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55ffb63b76eca2febf29dfd49e9c00fe
https://doi.org/10.1038/jhg.2016.15
https://doi.org/10.1038/jhg.2016.15
Autor:
Giuseppina Leonetti, Angela Polizzi, Maria Favia, Crescenzio Gallo, Antonio Manca, Stefano Castellani, Teresa Santostasi, Lorenzo Guerra, Pasqualina Montemurro, Valeria Casavola, Susanna D’Oria, Massimo Conese, Maria Addolorata Mariggiò
Publikováno v:
Pediatric pulmonology. 52(7)
Aim The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator ivacaftor (Kalydeco®) improves clinical outcome in G551D cystic fibrosis (CF) patients. Here, we have investigated whether ivacaftor has a clinical impact on non-G551D ga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89645a123669feb9f928bc08f7d0dd92
https://pubmed.ncbi.nlm.nih.gov/28445004
https://pubmed.ncbi.nlm.nih.gov/28445004